RJA
MBRX icon

Raymond James & Associates’s Moleculin Biotech MBRX Stock Holding History

Raymond James & Associates’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-38
Closed -$43K – 4227
2021
Q3 		$43K Sell
38
-2
-5% -$2.33K ﹤0.01% 3928
2021
Q2 		$55K Hold
40
– – ﹤0.01% 3906
2021
Q1 		$61K Buy
+40
New +$73.3K ﹤0.01% 3837

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return

Raymond James & Associates's MBRX Position: Q4 2021 in Review

Raymond James & Associates sold out of Moleculin Biotech (MBRX) in Q4 2021, closing a stake of 38 shares — an estimated $43K sold.

Raymond James & Associates first reported a position in MBRX in Q1 2021 and held it in 3 quarters. The position peaked at $61K in Q1 2021. 25 funds tracked by Wall St. Rank hold MBRX as of Q4 2021.

  • Raymond James & Associates reported no remaining Moleculin Biotech position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 38 Moleculin Biotech shares in Q4 2021, an estimated $43K.
  • Raymond James & Associates first reported a position in Moleculin Biotech in Q1 2021 and held it in 3 quarters.
  • Raymond James & Associates's Moleculin Biotech position peaked at $61K in Q1 2021.
  • 25 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.